117 related articles for article (PubMed ID: 34388452)
1. Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody.
Park SW; Jun SY; Kim JS; Kim YS
Biochem Biophys Res Commun; 2021 Oct; 573():35-41. PubMed ID: 34388452
[TBL] [Abstract][Full Text] [Related]
2. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
3. Engineering of a tumor cell-specific, cytosol-penetrating antibody with high endosomal escape efficacy.
Kim JS; Park JY; Shin SM; Park SW; Jun SY; Hong JS; Choi DK; Kim YS
Biochem Biophys Res Commun; 2018 Sep; 503(4):2510-2516. PubMed ID: 30208519
[TBL] [Abstract][Full Text] [Related]
4. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
5. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
Vorobyeva A; Konovalova E; Xu T; Schulga A; Altai M; Garousi J; Rinne SS; Orlova A; Tolmachev V; Deyev S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392820
[TBL] [Abstract][Full Text] [Related]
7. Identification of Tumor Specific Peptide as EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application.
Ma X; Kang X; He L; Zhou J; Zhou J; Sturm MB; Beer DG; Kuick R; Nancarrow DJ; Appelman HD; Pang Z; Li W; Zhang C; Zhang W; Zhang Y; Wang TD; Li M
Mol Pharm; 2019 May; 16(5):2199-2213. PubMed ID: 30974945
[TBL] [Abstract][Full Text] [Related]
8. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
[TBL] [Abstract][Full Text] [Related]
9. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
10. Epithelial cell adhesion molecule (EpCAM) binding short peptides derived from antibody MOC-31; De-novo design, synthesis and their in-vitro evaluation.
Shinde SD; Rao KB; Behera SK; Arya N; Sahu B
Biochem Biophys Res Commun; 2022 Apr; 600():1-5. PubMed ID: 35182969
[TBL] [Abstract][Full Text] [Related]
11. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
13. EpCAM-targeted liposomal si-RNA delivery for treatment of epithelial cancer.
Bhavsar D; Subramanian K; Sethuraman S; Krishnan UM
Drug Deliv; 2016 May; 23(4):1101-14. PubMed ID: 25417832
[TBL] [Abstract][Full Text] [Related]
14. Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells.
Liang KH; Tso HC; Hung SH; Kuan II; Lai JK; Ke FY; Chuang YT; Liu IJ; Wang YP; Chen RH; Wu HC
Cancer Lett; 2018 Oct; 433():165-175. PubMed ID: 29981429
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability.
Baek DS; Kim JH; Kim YJ; Kim YS
Mol Pharm; 2018 Feb; 15(2):394-402. PubMed ID: 29232521
[TBL] [Abstract][Full Text] [Related]
16. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency.
Stefan N; Martin-Killias P; Wyss-Stoeckle S; Honegger A; Zangemeister-Wittke U; Plückthun A
J Mol Biol; 2011 Nov; 413(4):826-43. PubMed ID: 21963989
[TBL] [Abstract][Full Text] [Related]
17. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.
Li C; Wang Y; Zhang X; Deng L; Zhang Y; Chen Z
Int J Nanomedicine; 2013; 8():1051-62. PubMed ID: 23515368
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.
Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
[TBL] [Abstract][Full Text] [Related]
20. Wash-free and selective imaging of epithelial cell adhesion molecule (EpCAM) expressing cells with fluorogenic peptide ligands.
K C TB; Suga K; Isoshima T; Aigaki T; Ito Y; Shiba K; Uzawa T
Biochem Biophys Res Commun; 2018 Jun; 500(2):283-287. PubMed ID: 29660346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
